Doctor David Goodman Jr
Senior Research Associate
- Specialist in Infectious Diseases - RACP, ABIM
- Specialist in Addiction Medicine - ABPM
- PhD (University of New South Wales)
Medicine & Health
The Kirby Institute
David Goodman-Meza is a Senior Research Associate in the Kirby Institute, ʹڲƱ Sydney since 2024. He is a clinician-scientist with expertise in Infectious Diseases and Substance Use Disorders. He has expertise in using methods from artificial intelligence to identify people who inject drugs and evaluate clinical outcomes in electronic health records, as well as experience in conducting clinical trials. Prior to moving to the Kirby, he was based in the United States receiving several research grants from the U.S. National Institute on Drug Abuse (NIDA).
E-mail
- Publications
- Media
- Grants
- Awards
- Research Activities
- Engagement
- Teaching and Supervision
- 2025 - ʹڲƱ Health Services Research Seed Grant -Feasibility of a pilot one-stop test and treat intervention to increase hepatitis C treatment uptake within the Australian National HCV Point of Care Testing Program. Role: CIA
- 2022 – 2025 - US NIH/NIDA -Predicting fatal and non-fatal overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to target street-based addiction treatment and harm reduction services (R01DA057630).Role: MPI
- 2020 – 2022 -CA-California Bureau of Cannabis Control.CaliCANN: A Demographic Analysis of the California Licensed Cannabis Industry & Consumer Market.Role: PI
- 2020 – 2024 - USNIAID/HPTN/FHI/NIDAINTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care.Role: Site PI
- 2019 – 2024 - US NIH/NIDA -Using data science to measure the impact of opioid agonist therapy in patients admitted with Staphylococcus aureus bloodstream infections (1K08DA048163).Role: PI
- 2020 – 2021 - US NIH/NIMH-CHIPTS -Developing a community informed psychosocial intervention for women who inject drugs in Mexicali, Mexico.Role: PI
- 2019 – 2022 - Gilead -Adaptation and Testing of a Navigation Intervention for Hepatitis C and HIV co-infected Persons Leaving LA County Jail (IN-US-987-5579).Role: PI
- 2019 – 2020 - US NIH/NIMH - Preparing for Long-acting Injectable Treatment for HIV in Los Angeles (3P30MH058107-23S2) -Role: Co-Investigator
- 2019 – 2020 - US NIMH/CSPAR -Immunosuppression and Neurologic Infectious Diseases Linked with Prescription Opioid use in People Living with HIV (P30MH062512).Role: PI
2009 Best medical intern, Social Security Institute of Mexico, Tijuana, Mexico
2010 Excellence in Medicine, Pfizer Scientific Institute, Mexico City, Mexico
2011 University exit exam (EGEL-MD) with Outstanding Outcome Award, Universidad Autonoma de Baja California, Tijuana, Mexico
2011 Merit Scholar, Autonomous Universidad Autonoma de Baja California, Tijuana, Mexico
2014 Best overall house staff award PGY-1, Jacobi Medical Center, Bronx, NY
2015 Best resident teacher PGY-2, Jacobi Medical Center, Bronx, NY
2016 Teaching Star, Albert Einstein College of Medicine, Bronx, NY
2017 Fellow teaching award nominee, UCLA, Los Angeles, CA
2018 Conference on Retroviruses and Opportunistic Infections Young Investigator Award, Boston, USA
2018 NIDA Fellowship Immersion Training in Addiction Medicine Scholarship Awardee, Beverly, USA
2018 IDSA IDWeek Travel Grant, San Francisco, USA
2019 ASAM Ruth Fox Scholarship, Orlando, USA
2020 CPDD NIDA Director’s Travel Award, Hollywood, USA
2022 UCLA Department of Medicine Research Day – 1st place Junior Faculty Health Services Research, Los Angeles, USA
2023 NIDA ASSET fellow, San Diego, USA
2024 ʹڲƱ Dean's Award for Outstanding PhD Theses, Sydney, Australia